PCF updated on-line monographs (since PCF6 publication) November 2017 to May 2019

Monograph	Chapter	Update type	Comments	Updated
Antacids and antiflatulents	Chapter 01	Full review		Mar-18
Compound alginate products	Chapter 01	Discontinued		Mar-18
Prokinetics	Chapter 01	Minor change	Updates to Table 2 and a new paragraph in use section and supply	Mar-18
Simeticone	Chapter 01	Discontinued		Mar-18
Antihistaminic antimuscarinic antiemetics	Chapter 04	Full review		May-18
Ferrous sulfate	Chapter 09	Minor change	Box A IV iron simplified	May-18
Morphine	Chapter 05	Minor change	Cyclizine dose in Table ammended	May-18
QCG: Inoperable bowel obstruction	Chapter 04	Minor change	Cyclizine dose ammended	May-18
QCG: Nausea and vomiting	Chapter 04	Minor change	Cyclizine dose ammended	May-18
QCG: Vertigo	Chapter 04	Minor change	Cyclizine dose ammended	May-18
Vitamin K (previously phytomenadione)	Chapter 01	Full review		May-18
Antihistaminic antimuscarinic antiemetics	Chapter 04	Minor change	Table 1 footnotes updated/clarified	Jun-18
Discoloured urine	Chapter 08	Full review	Reviewed; no changes	Jul-18
Levetiracetam	Chapter 04	Full review		Jul-18
Methenamine hippurate	Chapter 08	Full review		Jul-18
Propofol	Chapter 13	Full review	Reviewed; no changes	Jul-18
Rifampicin	Chapter 06	Full review		Jul-18
Cannabinoids	Chapter 04	Full review		Sep-18
Bisphosphonates	Chapter 07	Full review		Oct-18
Denosumab	Chapter 07	New		Oct-18
H2-receptor antagonists	Chapter 01	Full review		Oct-18
Proton pump inhibitors	Chapter 01	Full review		Oct-18
Antidepressants	Chapter 04	Minor change	Cautions and Drug interactions: serotonin toxicity and QT prolongation	Jan-19
Mirtazapine	Chapter 04	Minor change	Pharmacology: new refs and interactions section	Jan-19
Olanzapine	Chapter 04	Minor change	Dose and use: SC use and in renal/hepatic impairment	Jan-19
Loperamide	Chapter 01	Minor change	Cautions: high plasma levels	Jan-19
Catheter patency	Chapter 08	Full review		Jan-19
Zinc	Chapter 09	Full review		Jan-19
Levetiracetam	Chapter 04	Minor change	Minor change to the sentence structure in cautions and drug interactions	Feb-19
Pancreatin	Chapter 01	Full review	·	Feb-19
QT prolongation	Chapter 20	Full review		Feb-19
Desmopressin	Chapter 07	Full review		Mar-19
Gabapentin and pregabalin	Chapter 04	Minor change	Minor change to include information regarding repsiratory depression	Mar-19
Haemostatics	Chapter 02	Full review		Mar-19
Hepatic	Chapter 18	Full review		Mar-19
Tamsulosin	Chapter 08	Full review		Mar-19
Urinary antimuscarinics	Chapter 08	Full review		Mar-19
Valproate	Chapter 04	Minor change	Minor change to include information regarding use in women of child-bearing potential	Mar-19
Topical Products for haemorrhoids	Chapter 01	Full review		Apr-19
Danazol	Chapter 07	Full review		Apr-19
Progestogens	Chapter 07	Full review		Apr-19
Bisphosphonates	Chapter 07	Minor change	Minor update post JPSM article to include new refs 48, 49 and 76	Apr-19
QCG: Use of transdermal fentanyl patches	Chapter 05	Minor change	Clarification of use of Micropore tape and removal of tegaderm	Apr-19
QCG: Use of transdermal buprenorphine patches	Chapter 05	Minor change	Clarification of use of Micropore tape and removal of tegaderm	Apr-19
Transdermal patches	Chapter 30	Minor change	Clarification of use of Micropore tape and removal of tegaderm	Apr-19
Furosemide	Chapter 02	Full review	•	May-19
Spironolactone	Chapter 02	Full review		May-19